

DIAGNOSTIC ACCURACY OF NONINVASIVE BONE TURNOVER MARKERS IN RENAL OSTEODYSTROPHY

Hanne Skou Jørgensen^{1,6}, Geert Behets³, Liesbeth Viaene⁴, Bert Bammens^{1,2}, Kathleen Claes^{1,2}, Bjorn Meijers^{1,2}, Maarten Naesens^{1,2}, Ben Sprangers^{1,2}, Dirk Kuypers^{1,2}, Etienne Cavalier⁵, Patrick D'Haese³, Pieter Evenepoel^{1,2}

¹Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven, Belgium

²Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Belgium

³Laboratory of Pathophysiology, University of Antwerp, Wilrijk, Belgium

⁴Department of Nephrology, Az Groeninge, Kortrijk, Belgium

⁵Department of Clinical Chemistry, Université de Liège, Liège, Belgium

⁶Department of Kidney Diseases, Aarhus University Hospital, Aarhus, Denmark

Abstract

Rationale & Objective: Bone biopsy remains the gold standard for diagnosing renal osteodystrophy as comparable noninvasive alternatives have yet to be established. This study investigated the diagnostic accuracy of biochemical markers of skeletal remodeling to predict bone turnover.

Study Design: Cross-sectional retrospective diagnostic test study.

Setting & Participants: Patients with chronic kidney disease glomerular filtration rate categories 4-5, including patients treated with dialysis (G4-G5D) and kidney transplant recipients with successful transiliac bone biopsies.

Tests Compared: Bone turnover as determined by bone histomorphometry was compared with the following biochemical markers: full-length (amino acids 1-84) "biointact" parathyroid hormone (PTH), bone-specific alkaline phosphatase (BsAP), intact procollagen type I N-terminal propeptide (PINP), and tartrate-resistant acid phosphatase isoform 5b (TRAP5b).

Outcome: Diagnostic performance was evaluated by area under the receiver operator characteristics curve (AUC), sensitivity, specificity, and negative and positive predictive values. Optimal diagnostic cutoffs were determined in an exploration cohort (n = 100) and validated in a separate cohort (n = 99).

Results: All biomarkers differed across categories of low 33 (17%), normal 109 (55%), and high 57 (29%) bone turnover. AUC values were in the range of 0.75-0.85. High negative predictive values ($\geq 90\%$) were found for both high and low bone turnover, indicating the ability to rule out both conditions using the suggested biomarker cutoffs. The highest diagnostic performances were seen with combinations of biomarkers, with overall diagnostic accuracies of 90% for high turnover, and 78% for low turnover. Results were comparable for kidney transplant candidates and recipients in a sensitivity analysis.

Limitations: The single-center approach and heterogeneity of the study cohort are main limitations of this study.

Conclusions: We conclude that the diagnostic performance of biochemical markers of bone turnover is acceptable, with clinical utility in ruling out both high and low turnover bone disease.

PLAIN-LANGUAGE SUMMARY

Skeletal remodeling is disturbed in chronic kidney disease, and knowledge of the bone turnover status may help guide treatment decisions. Currently, a bone biopsy is the diagnostic standard to evaluate bone turnover, but this invasive procedure is not well suited for everyday clinical practice. This study investigates the diagnostic potential of noninvasive biochemical bone turnover markers for a diagnosis of high or low bone turnover in patients with chronic kidney disease. Our results suggest that biomarkers may be used to rule out the presence of both high and low bone turnover with a high degree of certainty. The clinical implications of these findings are that biochemical bone turnover markers may aid treatment decisions and potentially decrease the need for invasive bone biopsies in patients with chronic kidney disease.

The transiliac bone biopsy remains the gold standard for diagnosing renal osteodystrophy.¹ However, due to its invasive nature, a bone biopsy is not recommended as part of routine clinical workup.² Rather, it is reserved for the in-depth evaluation of bone disease in select patients, such as in cases of skeletal fractures or bone pain, inconsistencies in biochemical parameters of mineral metabolism, before referrals for parathyroidectomy, or initiation of antiresorptive therapy.³ Suitable alternatives to the bone biopsy for evaluating renal osteodystrophy in everyday clinical practice have yet to be established.

In the most recent KDIGO (Kidney Disease: Improving Global Outcomes) guideline on mineral and bone disorder in chronic kidney disease (CKD),² circulating levels of parathyroid hormone (PTH) and bone-specific alkaline phosphatase (BsAP) are suggested as surrogate markers of bone turnover in CKD stages 3-5D, with the specification that both may predict bone turnover at markedly high or low levels. As a biomarker, however, PTH has several limitations, including a high biological variability and assay standardization issues.⁴ Further, skeletal sensitivity to PTH may be reduced in CKD,⁵ and this PTH hyporesponsiveness may depend on kidney function. Despite these limitations, PTH has long been the preferred marker of bone turnover in clinical practice, and novel biomarkers have so far failed to show diagnostic superiority, at least in patients with kidney failure.⁶⁻⁸

In contrast to PTH, which is a key regulator of bone metabolism, bone turnover markers are specifically released from bone cells during skeletal remodeling. BsAP is secreted by osteoblasts in the process of biomineralization,⁹ and procollagen type I N-terminal propeptide (PINP) is a fragment released when collagen is deposited in the bone matrix¹⁰; both are considered markers of bone formation. Importantly, monomeric fragments of PINP accumulate in CKD, necessitating the use of assays specific for the intact, trimeric form.¹¹ Tartrateresistant acid phosphatase isoform 5b (TRAP5b) is an enzyme originating from osteoclasts and considered a highly specific marker of bone resorption.¹² As none of

these 3 biomarkers are influenced by kidney function, they may be particularly well suited for use in patients with CKD.¹³

The primary aim of the present study was to investigate the diagnostic accuracy of a panel of biochemical markers of skeletal remodeling as compared with full-length PTH using the histomorphometric evaluation of bone turnover as the diagnostic standard. We hypothesized that biochemical markers of bone turnover would outperform PTH for a diagnosis of high or low bone turnover in patients with CKD.

Methods

COHORT

Patients with CKD and a tetracycline-labeled bone biopsy of sufficient quality for a full histomorphometric analysis were eligible to be included. All patients had agreed to participate in a prospective, observational study on the natural history of mineral and bone disorder after kidney transplantation (ClinicalTrials.gov identifier, NCT01886950). Use of antiosteoporotic treatment was the only exclusion criterion. All bone biopsies were performed between April 2011 and September 2018 at Leuven University Hospitals in Belgium. A flow chart of patient inclusion and exclusion is provided as Figure S1.

Relevant demographic variables and details of medical therapy were extracted from electronic patient files. For kidney transplant recipients, immunosuppression was achieved with glucocorticoids, a calcineurin inhibitor, and an antimetabolite. Methylprednisolone was administered intravenously on the day of transplantation (500 mg) and the first postoperative day (40 mg), followed by a daily dose of 16 mg of prednisolone orally, tapered gradually over the first 3 months. The clinical course, together with findings on a protocolled kidney graft biopsy at month 3, determined if glucocorticoids were discontinued.

All clinical and research activities reported are consistent with the principles of the Declaration of Istanbul. The study adhered to the principles of the Declaration of Helsinki and was approved by the Ethical Committee of KU Leuven (study identifier: S52091). All participants provided written informed consent.

BIOCHEMICAL ANALYSES

Blood samples were taken on the day of the bone biopsy procedure after an overnight fast. Whole blood samples were stored for less than 2 hours at 5 C before arrival at the laboratory, where they were centrifuged at 3,000 rpm for 10 minutes, after which serum samples were aliquoted and stored at -80 C until analysis. Creatinine, hemoglobin, phosphate, total calcium, and total alkaline phosphatase (AP) were measured using standard laboratory techniques. The estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI equation.¹⁴

Serum 25-hydroxyvitamin D (calcidiol) was measured using a radioimmunoassay.¹⁵ Serum concentrations of fulllength, “biointact” PTH (ie, containing amino acids 1-84) was determined by an in-house immunoradiometric assay (reference range, 3-40 pg/mL).¹⁶ Bone-specific alkaline phosphatase (BsAP) (reference range, 6.1-25.5 µg/L; assay range, 1-75 µg/L), trimeric procollagen type I N-terminal propeptide (PINP) (reference range, 12.8-82.6 ng/mL; assay range, 2-230 ng/mL), and tartrate-resistant acid phosphatase isoform 5b (TRAP5b) (reference range, 1.16.9 U/L; assay range, 0.9-14.0 U/L) were measured with the ImmunoDiagnostic Systems iSYS instrument (IDS). Interassay and intra-assay variations were below 10% for all assays used. Values of BsAP, intact PINP, and TRAP5b above the upper limit of quantification of the respective assays were determined after dilution.

BONE HISTOMORPHOMETRY

The bone biopsy was performed as an outpatient procedure under light sedation with local anesthesia. Using an 7G trephine with an outer/inner diameter of 4.50/3.55 mm (Biopsybell), the sample was retrieved from a site 2 cm posterior and 2 cm inferior to the anterior iliac spine. Complications occurred in 7 patients and included prolonged postprocedural pain (n = 6) and bleeding requiring transfusion (n = 1). All biopsies were preceded by double tetracycline labeling by the following protocol: tetracycline was administered orally (500 mg × 2 daily for 3 days) for 2 sessions with a tetracycline-free interval of 11 days, and the bone biopsy was scheduled 4 days after the last intake of tetracycline. To avoid a systematic bias caused by lack of tetracycline labels in very low bone turnover, biopsies without visible tetracycline labels were included if the patient was noted to have taken tetracycline and static histomorphometry was consistent with low turnover. In such cases, the bone formation rate (BFR) per total tissue volume was set arbitrarily at 1 mm³/cm³/y (n = 12).¹⁷ Similarly, patients with a very high bone turnover and diffuse, unmeasurable labels (n = 2) were not excluded, and a value of 712 mm³/cm³/y was set for the BFR, corresponding to 20% above the highest measured BFR in this cohort (594 mm³/cm³/y).

Bone cores were fixed in 70% ethanol and embedded in a methylmethacrylate resin. Undecalcified 5-µm thick sections were stained by the Goldner method to determine static bone parameters, and unstained 10-µm thick sections were mounted in 100% glycerol for fluorescence microscopy to visualize tetracycline labels and determine the dynamic parameters. All bone histomorphometric analyses were performed at the Laboratory of Pathophysiology, University of Antwerp, Belgium, running a custom program on the commercially available image analysis software AxioVision (version 4.51, Zeiss Microscopy). Bone histomorphometric parameters are reported in 2 dimensions using standardized nomenclature,¹⁷ following the recommended approach of evaluating bone turnover, mineralization, and volume.¹ Patients were categorized as having low, normal, or high bone turnover based on the BFR per total tissue volume, using a normal range of 11.5-110 mm³/cm³/y, as previously determined in an adult reference population.^{18,19}

STATISTICAL ANALYSIS

Descriptive statistics are presented as mean ± SD, median and interquartile range (IQR), or number and percentage, as appropriate. Differences in biomarker levels across categories of bone turnover were

tested by one-way analysis of variance (ANOVA), followed by t test against the “normal” group, using the natural logarithms of biomarkers to achieve normal distribution.

The diagnostic ability of biomarkers were evaluated by area under the receiver operator characteristics curve (AUC) statistics,²⁰ running a nonparametric and bootstrapped estimation for each biomarker. AUC values were designated as poor (<0.6), fair (0.6-0.7), good (0.7-0.8), very good (0.8-0.9), or excellent (>0.90). Optimal cutoffs were determined by Liu's method²¹ as the biomarker level resulting in the maximum product of sensitivity and specificity. To avoid model optimism, we randomly split the cohort into separate exploration (n = 100) and validation (n = 99) subsets.

Estimation of the optimal cutoff of each biomarker was performed in the exploration cohort, and the diagnostic performances of these cutoffs were subsequently evaluated in the validation cohort. To account for the effect of disease prevalence on test performance, we adjusted the negative and positive predictive values for pretest probability (ie, prevalence of disease) according to Bayes' theorem (Figure S2).²² Finally, as a sensitivity analysis, we conducted AUC analyses for patients biopsied before or after kidney transplantation as 2 separate groups. Statistical analyses were performed using STATA IC version 16.1 (StataCorp LP).

Results

COHORT

Out of 286 available biopsies, 19 were of insufficient quality for a full histomorphometric analysis, and 22 were without successful tetracycline labeling. Further, 35 patients were excluded to avoid duplicates, 4 due to bisphosphonate use, 4 due to recent fracture (<6 months), and 3 due to missing biochemistry, leaving a cohort of 199 patients for analysis (Fig S1). The majority of bone biopsies were performed solely as part of a research protocol (n = 187 [95%]), while the remaining 12 patients were biopsied on indication.

DEMOGRAPHY

The mean age of the participants was 55 ± 13 years; two-thirds were men (67%), and 23% had diabetes mellitus. The cause of CKD was as follows: cystic or hereditary disease (n = 49 [25%]), glomerulonephritis or vasculitis (n = 49 [25%]), hypertension or large vessel disease (n = 17 [8.5%]), diabetic nephropathy (n = 15 [7.5%]), interstitial nephritis (n = 15 [7.5%]), miscellaneous (n = 7 [3.5%]), or unknown (n = 47 [24%]). Demographic data for the participating kidney transplant candidates (n = 80) and recipients (n = 119) are given in Table 1.

The kidney transplant candidates were CKD glomerular filtration rate category 4 (G4; n = 7), G5 (n = 7), or G5 treated by dialysis (G5D; n = 66). Among patients with CKD G5D, 44 received maintenance intermittent hemodialysis therapy and 22 continuous peritoneal dialysis treatment, with a median dialysis vintage of 15 (IQR, 926) months.

Table 1. Demographic Data in the Overall Cohort and Separated by Time of Bone Biopsy Before or After Kidney Transplantation

	CKD G4-G5D (n = 80)	Kidney Transplant Recipients (n = 119)
Age, y	53 ± 14	57 ± 11
Male sex	49 (61%)	85 (71%)
Diabetes mellitus, any type	8 (10%)	37 (31%)
Previous parathyroidectomy	5 (6%)	16 (14%)
Body mass index, kg/m ²	24.4 ± 4.6	25.3 ± 4.8
Bone turnover		
Low	6 (8%)	27 (23%)
Normal	38 (47%)	71 (60%)
High	36 (45%)	21 (18%)
Bioactive PTH, pg/mL	277 [111-461]	59 [40-110]
Total AP, U/L	112 [91-168]	79 [59-98]
Total calcium, mg/dL	9.46 ± 0.76	9.87 ± 0.79
Phosphate, mg/dL	5.66 ± 1.70	3.09 ± 0.83
Calcidiol, ng/mL	38 ± 17	36 ± 14
BsAP, µg/L	37.2 [24.7-58.3]	21.8 [14.2-31.7]
Intact PINP, ng/mL	108.2 [61.1-167.3]	55.0 [30.1-98.8]
TRAP5b, U/L	6.1 [4.4-8.3]	3.5 [2.5-4.9]
Cinacalcet hydrochloride	6 (8%)	2 (2%)
Vitamin D	55 (69%)	53 (45%)
Active vitamin D	42 (53%)	20 (17%)
Methylprednisolone	18 (23%)	88 (74%)

Data are mean ± SD, median [interquartile range], or n (%). Abbreviations: AP, alkaline phosphatase; BsAP, bone-specific alkaline phosphatase; CKD G4-G5D, chronic kidney disease glomerular filtration rate categories 4-5, including patients treated with dialysis; PINP, procollagen type I N-terminal propeptide; PTH, parathyroid hormone; TRAP5b, tartrate resistant acid phosphatase isoform 5b.

The kidney transplant recipients were mainly biopsied at 12 months after transplantation (n = 103), with 6 patients biopsied earlier and 10 patients later than this time point. Kidney transplant recipients had a mean eGFR of 50 ± 15 mL/min/1.73 m²; 8 patients had an eGFR < 30, and none had an eGFR < 15 mL/min/1.73 m². The immunosuppressive regimen consisted of a calcineurin inhibitor in combination with mycophenolate mofetil (MMF) for the majority (n = 110 [92%]); 8 patients received a calcineurin inhibitor without MMF, and 1 patient received MMF alone. Tacrolimus was the most common calcineurin inhibitor used, with only 2 patients receiving cyclosporine A. Prednisolone had been halted in 33 (28%) patients; for the remaining patients the daily doses were ≤4 mg (n = 85), with a single patient receiving 10 mg. The median cumulative steroid dose at 12 months after transplantation was 2.54 (IQR, 1.81-3.14) g.

BIOCHEMICAL MARKERS OF BONE TURNOVER

Bone turnover was classified as low in 33 (17%), normal in 109 (55%), and high in 57 (29%) patients. Levels of biochemical markers by categories of bone turnover are given in Table 2 and Figure 1. Highly significant differences in circulating levels were seen for all markers across bone turnover categories, although with a noticeable overlap in biomarker range, particularly between patients with low and normal bone turnover.


Moderate, highly significant correlations were seen between the levels of biochemical markers and dynamic and static parameters of skeletal remodeling (Table 3). The bone turnover markers were all significantly correlated to PTH (ρ, 0.45-0.52, P < 0.001) and to each other (ρ, 0.76-0.79, P < 0.001).

Table 2. Biochemical Markers by Category of Bone Turnover

	Reference Range	Low (n = 33)	Normal (n = 109)	High (n = 57)	P
Biointact PTH, pg/mL	3-40	53.2 [36.8-86.5]	77.6 [43.4-175.0]	249.0 [114.5-428.6]	<0.001
Biointact PTH, ×UNL	<1	1.3 [0.9-2.2]	1.9 [1.1-4.4]	6.2 [2.9-10.7]	<0.001
Total AP, U/L	35-130	63.0 [47.2-86.8]	86.7 [69.0-109.0]	125.0 [101.0-182.1]	<0.001
BsAP, µg/L	6.1-25.5	15.3 [11.1-22.1]	24.7 [16.3-34.2]	47.4 [33.8-66.8]	<0.001
Intact PINP, ng/mL	12.8-82.6	31.5 [23.1-44.7]	66.1 [39.7-95.0]	154.7 [119.0-219.8]	<0.001
TRAP5b, U/L	1.1-6.9	2.7 [1.9-3.4]	4.1 [2.8-5.8]	6.4 [5.1-8.5]	<0.001

Data are median [interquartile range] with P values by Kruskal Wallis equality-of-populations rank test. Abbreviations: AP, alkaline phosphatase; BsAP, bone-specific alkaline phosphatase; PINP, procollagen type I N-terminal propeptide; PTH, parathyroid hormone; TRAP5b, tartrate-resistant acid phosphatase isoform 5b; ×UNL, times the upper limit of normal range.

Figure 1. Distribution of biointact PTH, BsAP, PINP, and TRAP5b across categories of low, normal, and high bone turnover as evaluated by bone histomorphometry. Abbreviations: BsAP, bone-specific alkaline phosphatase; PINP, procollagen type I N-terminal propeptide; PTH, parathyroid hormone; TRAP5b, tartrate-resistant acid phosphatase isoform 5b; ×UNL, times the upper limit of normal range.



DIAGNOSTIC PERFORMANCE OF BIOMARKERS

Figure 2 shows areas under the receiver operator characteristics curve (AUCs) for separating bone turnover in the overall cohort as high versus nonhigh, and low versus nonlow. Discriminatory ability was consistently very good for both high and low bone turnover (with AUCs > 0.80 for the bone turnover markers) while slightly lower (AUCs > 0.75) for biointact PTH and total AP. Compared to biointact PTH, intact PINP was a significantly better predictor of high turnover (AUCs of 0.88 vs 0.78, $P = 0.006$), and TRAP5b was a better predictor for low turnover (AUCs of 0.82 vs 0.73, $P = 0.04$).

To evaluate diagnostic performance, we randomly split the cohort into separate exploration ($n = 100$) and validation ($n = 99$) subsets. The distribution of bone turnover categories, demographic characteristics, and levels of biochemical markers were balanced between the exploration and validation cohorts (Table S1).

Table 3. Correlations Between Biochemical Markers of Bone Turnover and Bone Histomorphometry

	Biointact PTH, pg/ mL	Total AP, U/L	BsAP, µg/L	Intact PINP, ng/mL	TRAP5b, U/L
Turnover					
BFR, mm ³ / cm ³ /y	0.509 ^a	0.520 ^a	0.631 ^a	0.693 ^a	0.615 ^a
Osteoblast/ bone perimeter, %	0.505 ^a	0.262 ^b	0.393 ^a	0.434 ^a	0.404 ^a
Eroded/bone perimeter, %	0.443 ^a	0.269 ^a	0.293 ^a	0.366 ^a	0.478 ^a
Osteoclast/ bone perimeter, %	0.438 ^a	0.260 ^c	0.320 ^a	0.374 ^a	0.459 ^a
Mineralization					
Mineralization lag time, d	-0.149	-0.201	-0.211	-0.317 ^a	-0.305 ^a
Osteoid/bone area, %	0.409 ^a	0.344 ^a	0.450 ^a	0.396 ^a	0.378 ^a
Osteoid/bone perimeter, %	0.452 ^a	0.305 ^c	0.426 ^a	0.397 ^a	0.359 ^a
Osteoid width, µm	0.216 ^b	0.318 ^a	0.342 ^a	0.332 ^a	0.274 ^c


Abbreviations: AP, alkaline phosphatase; BFR, bone formation rate (per total tissue volume); BsAP, bone-specific alkaline phosphatase; PINP, procollagen type I N-terminal propeptide; PTH, parathyroid hormone; TRAP5b, tartrate-resistant acid phosphatase isoform 5b.

^aSpearman ρ with $P < 0.001$ after Bonferroni adjustment for multiple comparisons.

^bSpearman ρ with $P < 0.05$ after Bonferroni adjustment for multiple comparisons.

^cSpearman ρ with $P < 0.01$ after Bonferroni adjustment for multiple comparisons.

Figure 2. Areas under the receiver operator characteristics curves for the diagnosis of bone turnover by biochemical markers biointact PTH, tAP and BsAP, PINP, and TRAP5b in the overall cohort (n = 199); *P < 0.05 compared with biointact PTH. Abbreviations: BsAP, bone-specific alkaline phosphatase; PINP, procollagen type I N-terminal propeptide; PTH, parathyroid hormone; ROC, receiver operating characteristic; AP, total alkaline phosphatase; TRAP5b, tartrate-resistant acid phosphatase isoform 5b.



Optimal diagnostic cutoffs for high versus nonhigh and low versus nonlow bone turnover were determined based on receiver operating characteristic curves in the Table 2. Biochemical Markers by Category of Bone Turnover exploration cohort and then applied to the validation cohort to evaluate diagnostic performance. Results are shown in Table 4. Negative predictive values were high, indicating the ability to rule out both high and low bone turnover by using the suggested cutoffs. Combinations of bone turnover markers resulted in slightly higher diagnostic performance, with overall accuracies of 90% for high turnover, using the combination of intact PINP and TRAP5b, and 78% for low turnover with the combination of BsAP and TRAP5b. Combinations of markers also resulted in high positive predictive values for a diagnosis of high turnover, indicating greater surety of the diagnosis with 2 biomarkers above the cutoffs.

Table 4. Diagnostic Performance of Biochemical Markers for a Diagnosis of High or Low Bone Turnover

	Exploration Cohort (n = 100)		Validation Cohort (n = 99)				
	AUC	Cutoff	Sensitivity	Specificity	PPV	NPV	Accuracy
High Turnover							
Biointact PTH, pg/mL	0.78 (0.67, 0.86)	>143.5	70%	74%	57%	84%	73%
Total AP, U/L	0.77 (0.65, 0.86)	>97	76%	77%	61%	87%	77%
BsAP, µg/L	0.83 (0.73, 0.91)	>33.7	73%	86%	71%	88%	82%
Intact PINP, ng/mL	0.85 (0.74, 0.93)	>120.7	73%	94%	85%	89%	88%
TRAP5b, U/L	0.78 (0.66, 0.86)	>5.05	77%	76%	59%	88%	76%
BsAP + intact PINP	0.84 (0.74, 0.94)	As above	63%	97%	90%	85%	86%
BsAP + TRAP5b	0.79 (0.70, 0.88)	As above	63%	91%	76%	85%	82%
PINP + TRAP5b	0.84 (0.74, 0.94)	As above	82%	94%	88%	91%	90%
Low Turnover							
Biointact PTH, pg/mL	0.77 (0.65, 0.86)	<90.5	69%	52%	19%	91%	54%
Total AP, U/L	0.76 (0.63, 0.85)	<87	64%	57%	21%	90%	58%
BsAP, µg/L	0.82 (0.72, 0.90)	<24.2	87%	58%	28%	96%	63%
Intact PINP, ng/mL	0.83 (0.72, 0.91)	<49.8	80%	70%	33%	95%	72%
TRAP5b, U/L	0.84 (0.74, 0.91)	<3.44	73%	74%	34%	94%	74%
BsAP + intact PINP	0.84 (0.75, 0.93)	As above	73%	74%	34%	94%	74%
BsAP + TRAP5b	0.86 (0.79, 0.94)	As above	60%	81%	38%	92%	78%
PINP + TRAP5b	0.85 (0.77, 0.93)	As above	67%	77%	34%	93%	72%

AUC and cutoffs as determined by Liu's method²¹ were calculated using the exploration cohort only. Sensitivity, specificity, NPV, and PPV were calculated for the validation cohort only, using the specified cutoffs. For combined biochemical markers, both markers were above/below the cutoff for a positive test result, while either above/below were counted as a negative test result. Abbreviations: AP, alkaline phosphatase; AUC, area under the receiver operator characteristics curve; BsAP, bone-specific alkaline phosphatase; NPV, negative predictive value; PINP, procollagen type I N-terminal propeptide; PPV, positive predictive value; PTH, parathyroid hormone; TRAP5b, tartrate-resistant acid phosphatase isoform 5b.

As a sensitivity analysis, we repeated the AUC analysis separating kidney transplant candidates and recipients. The results are shown in Table 5. The discrimination of high bone turnover was similar comparing patients with CKD G4-G5D and kidney transplant recipients, while for low bone turnover the AUC values were numerically lower in patients biopsied after kidney transplantation, particularly for biointact PTH.

Finally, to account for the effect of disease prevalence on diagnostic test interpretation, we calculated negative and positive predictive values for any possible prevalence of high and low bone turnover (ie, from 0 to 100%). The results are shown in Figure S2. The ability to rule out high and low bone turnover using biomarker cutoffs was found to be acceptable (>90%) with prevalence of either condition below 30%.

Table 5. Discriminatory Ability of Biochemical Markers for High and Low Bone Turnover Stratified by Kidney Transplantation Status

	High vs Nonhigh Turnover		Low vs Nonlow Turnover	
	CKD G4-G5D (36 vs 44)	Kidney Transplant Recipients (21 vs 98)	CKD G4-G5D (6 vs 74)	Kidney Transplant Recipients (27 vs 92)
Bioactive PTH, pg/mL	0.66 (0.54-0.79)	0.76 (0.63-0.89)	0.82 (0.64-0.99)	0.61 (0.49-0.74)
Total AP, U/L	0.69 (0.57-0.81)	0.74 (0.60-0.89)	0.85 (0.73-0.97)	0.69 (0.56-0.81)
BsAP, µg/L	0.78 (0.67-0.89)	0.80 (0.68-0.92)	0.94 (0.86-1.00)	0.74 (0.64-0.84)
Intact PINP, ng/mL	0.84 (0.75-0.93)	0.87 (0.77-0.97)	0.89 (0.77-1.00)	0.77 (0.67-0.87)
TRAP5b, U/L	0.75 (0.64-0.86)	0.78 (0.65-0.91)	0.93 (0.87-1.00)	0.74 (0.65-0.84)

Data are area under the receiver operator characteristics curve with 95% confidence intervals for high versus nonhigh, and low versus nonlow bone turnover. Abbreviations: AP, alkaline phosphatase; BsAP, bone-specific alkaline phosphatase; CKD G4-G5D, chronic kidney disease glomerular filtration rate categories 4-5, including patients treated with dialysis; PINP, procollagen type I N-terminal propeptide; PTH, parathyroid hormone; TRAP5b, tartrate-resistant acid phosphatase isoform 5b.

Discussion

The key finding of this study is that biochemical markers of skeletal remodeling show acceptable diagnostic accuracy for bone turnover both in patients with CKD G4-G5D and in kidney transplant recipients. High negative predictive values suggest that measurement of biochemical markers of skeletal remodeling might rule out the presence of high and low bone turnover, which could potentially decrease the need for an invasive bone biopsy.

The discriminatory abilities of all biochemical markers were good, with AUC values > 0.80 for both high and low bone turnover using the bone turnover markers, and slightly lower values for bioactive PTH and total AP. The calculated cutoffs in the exploration cohort resulted in sensitivities and specificities in the range of 70%-95% for high turnover disease, and 60%-85% for low turnover disease, with the highest values for BsAP, intact PINP, and TRAP5b. These results are largely in accordance with what have been published previously.^{6,8,23,24}

Predictive values of negative and positive test results are often given to illustrate clinical usefulness. High negative predictive values were seen for both high and low bone turnover, suggesting that either condition might be ruled out using the suggested cutoffs. Further, with 2 markers above the cutoffs, positive predictive values up toward 90% were seen for high bone turnover. This could find clinical utility as an aid to treatment decisions—for example, by ruling out the presence of low turnover disease when considering initiation of antiresorptive treatment or by estimating the likelihood of high bone turnover when considering whether to intensify treatment for secondary hyperparathyroidism. Positive predictive values for low turnover, however, were consistently very poor and did not improve by combining markers.

Although BsAP has been extensively investigated,^{6-8,25-28} only a few studies previously examined the diagnostic value of the more novel markers intact PINP and TRAP5b.^{23,24} Sprague et al⁶ included PINP in their multicenter study of diagnostic accuracy of biomarkers in patients with kidney failure but did not measure the intact, trimeric form. Because monomers of PINP accumulate in CKD, total PINP is affected by kidney function²⁹; in the study by Sprague et al,⁶ any residual kidney function in the participating dialysis patients could have affected the results. Salam et al²³ reported the diagnostic performance of a panel of bone turnover markers in patients with CKD G4-G5D. Discrimination of low turnover was found to be good, particularly for BsAP, intact PINP, and TRAP5b (AUCs of 0.79-0.80) while significantly

less so for intact PTH (AUC of 0.56). We note that the calculated cutoffs for high and low turnover reported by Salam et al²³ were very similar to what we demonstrated in our present study, which shows consistency across different study populations.

We hypothesized that the bone turnover markers would provide a better diagnostic performance when compared to PTH. As BsAP, PINP, and TRAP5b are released from the bone tissue during the skeletal remodeling process, they have the potential to deliver highly specific information on whole-skeletal bone turnover. In contrast, PTH is a main regulator of skeletal remodeling and may be competing with other effectors on the bone, such as hypogonadism, steroid exposure, inflammation, and uremic toxins,³⁰ leading to a poorer prediction of the current skeletal remodeling rate. However, although there were indications of better diagnostic accuracy for the bone turnover markers compared to PTH, based on higher AUC values, the differences in diagnostic performance as judged by the values of negative and positive test results were negligible. Similarly, Salam et al²³ found significantly better prediction of low bone turnover by bone turnover markers as compared to intact PTH in patients with CKD G4-G5D, but again the effect on test performance was small. The intact PTH assay captures not only the full-length (amino acids 1-84) PTH, but also various PTH fragments, and as these are retained in CKD,^{31,32} PTH measured by the intact assay could be expected to perform less well, particularly in cohorts spanning different CKD stages. We measured biointact (full-length) PTH in this study, so any accumulation of fragments should not affect our results. It remains uncertain whether there is a benefit of measuring the complete hormone; in the previously mentioned study by Sprague et al,⁶ no difference in diagnostic accuracy for bone turnover was found for biointact versus intact PTH.


Diagnostic performance of biomarkers for high bone turnover was comparable for patients with CKD G4-G5D and kidney transplant recipients—but with numerically lower AUCs for low bone turnover in posttransplant patients. The posttransplant bone phenotype is a composite of renal osteodystrophy before transplant, of resolving or ongoing disturbances of mineral metabolism, and of effects of immunosuppressants on bone. Profound alterations in mineral metabolism occur after kidney transplantation, and although kidney function and biochemical parameters generally stabilize by 3 months,^{33,34} persistent disturbances are seen in subsets of patients throughout the first posttransplant year.^{35,36} Marked variability in the histomorphometric pattern even within the same bone sample has been demonstrated in kidney transplant recipients,³⁷ which may reflect a slow transition to a new skeletal steady state. By contrast, biochemical markers of bone turnover are highly dynamic, as seen by the rapid changes in circulating levels in response to fracture³⁸ and antiosteoporotic treatment.³⁹ This time lag between bone turnover as evaluated by histomorphometry versus biochemistry may contribute to a lower diagnostic accuracy of biomarkers in the posttransplant setting. A steroid-minimization protocol was used in the study period. Still, 74% of patients received oral prednisolone at the time of the bone biopsy. Glucocorticoids result in a sustained depression of osteoblast function, with more transient increase in osteoclast activity.⁴⁰ Thus, the effect of glucocorticoids may contribute to a more severe phenotype of low bone turnover after transplant.

The main strength of this study is the considerable number of bone biopsies available for evaluation. Further, we limited our analyses to high quality, successfully labeled bone biopsies, and all histomorphometric analyses were performed at the same laboratory, which avoided variability in sample processing, reference cutoffs, and diagnostic practice. To reduce optimism bias when evaluating diagnostic performance, we used an explorative subset of patients for estimating the

diagnostic cutoffs, which were then validated in a separate subset. However, no external validation was performed, which, together with the single-center approach and ethnically homogenous cohort, may reduce the reproducibility of our findings.

The heterogeneity in our cohort may be considered a limitation because we included patients with CKD G4-G5D as well as kidney transplant recipients. However, we are not aware of the stage of CKD affecting the relationship between skeletal remodeling and release of biomarkers from the bone tissue; also, as already detailed, the biomarkers included in this study do not accumulate with decreasing kidney function.¹³ The blood sampling in patients with CKD G5D was random with regard to the last dialysis session, but the effect of hemodialysis therapy on circulating levels of bone turnover markers has previously been shown to be limited.^{41,42} Any effect of peritoneal dialysis treatment on circulating biomarker levels has, to our knowledge, not yet been investigated; but considering the continuous nature of this treatment, it should likewise be minimal.

An inherent limitation to these analyses is the consideration that the circulating bone turnover markers must represent whole skeletal metabolism, including both the central and distal skeleton and cortical and trabecular bone compartments. By contrast, the bone biopsy is representative of a single skeletal site only and the trabecular bone compartment specifically. In accordance, rather weak correlations were found between bone biomarkers and histomorphometric parameters in postmenopausal women.⁴³ Recent pilot trials have highlighted the potential of bone turnover markers to deliver dynamic information, with changes in circulating levels reflecting the treatment effects on skeletal remodeling^{44,45}; this is a clear advantage as opposed to the bone biopsy, which cannot easily be repeated. Finally, the predictive ability of these markers on relevant clinical outcomes has yet to be established and will likely require the collaborative effort of multiple centers with expertise within this field.⁴⁶



Supplementary Material

[Supplementary File \(PDF\)](#)

Figure S1: Flow chart of patient inclusion and exclusion.

Figure S2: Negative and positive predictive values of high and low bone turnover using biomarker cutoffs as a function of prevalence of disease.

Table S1: Balance of demographic and biochemical variables in the validation and exploration cohorts.

Article Information

Authors' Full Names and Academic Degrees: Hanne Skou Jørgensen, MD, PhD, Geert Behets, PhD, Liesbeth Viaene, MD, PhD, Bert Bammens, MD, PhD, Kathleen Claes, MD, PhD, Bjorn Meijers, MD, PhD, Maarten Naesens, MD, PhD, Ben Sprangers, MD, PhD, Dirk Kuypers, MD, PhD, Etienne Cavalier, MD, PhD, Patrick D'Haese, PhD, and Pieter Evenepoel, MD, PhD.

Authors' Affiliations: Department of Microbiology, Immunology and Transplantation; Nephrology and Renal Transplantation Research Group, KU Leuven, Belgium (HSJ, BB, KC, BM, MN, BS, DK, PE); Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Belgium (BB, KC, BM, MN, BS, DK, PE); Laboratory of Pathophysiology, University of Antwerp, Wilrijk, Belgium (GB, PD); Department of Nephrology, Az Groeninge, Kortrijk, Belgium (LV); Department of Clinical Chemistry, Universite de Liege, Liege, Belgium (EC); and Department of Kidney Diseases, Aarhus University Hospital, Aarhus, Denmark (HSJ).

Address for Correspondence: Peter Evenepoel, MD, PhD, Division of Nephrology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. Email: pieter.evenepoel@uzleuven.be

Authors' Contributions: Research idea and study design: PE, EC, PD; data acquisition: LV, BB, KC, BM, MN, BS, DK; data analysis/ interpretation: HSJ, PD'H, EC, PE; statistical analysis: HSJ; supervision or mentorship: PE. GB was not available to confirm coauthorship; PD affirms that he contributed to data acquisition and data analysis/interpretation and vouches for his coauthorship status; all other authors approved the final author list. Except as noted, each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate.

Support: This work was supported by an ERA-EDTA long-term fellowship in the CKD-MBD working group (to HSJ), and received financial support from the Augustinus Foundation and Kornings Fund (to HSJ); and a grant from FWO Onderzoeksproject (to LV). BS and MN are senior clinical investigators of the Research Foundation Flanders (1842919N and 1844019N, respectively). No funders had any role in study design, data collection, data analysis, draft preparation, or the decision to submit this paper for publication.

Financial Disclosure: Dr Viaene has received personal fees from Amgen, outside the submitted work. Dr Bammens has received grants and other support from Otsuka Pharmaceutical, and other support from Baxter, outside the submitted work. Dr Claes has received other support from Astellas, Astra Zeneca, and Alexion, outside the submitted work. Dr Meijers has received grants and personal fees from Nipro and personal fees from Astra Zeneca, Baxter, and Bayer, outside the submitted work. Dr Cavalier has received other support from IDS, DiaSorin, Fujirebio, Menarini, and bioMerieux, outside the submitted work. Dr Evenepoel has received personal and other fees from Amgen, outside the submitted work. Drs Sprangers and Naesens are senior clinical investigators of the Research Foundation Flanders (1842919N and 1844019N, respectively). The remaining authors declare that they have no relevant financial interests.

Acknowledgements: The authors would like to acknowledge the excellent technical support of Marc Dekens and Henriette de Loor, and also thank the centers of the Leuven Collaborative Group for Renal Transplantation, the clinicians and surgeons, nursing staff, and patients.

Peer Review: Received February 18, 2021. Evaluated by 3 external peer reviewers, with direct editorial input from a Statistics/Methods Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form July 23, 2021.

References

1. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int.* 2006;69(11):1945-1953. doi:10.1038/sj.ki.5000414
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). *Kidney Int Suppl.* 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001
3. Torres PU, Bover J, Mazzaferro S, de Vernejoul MC, CohenSolal M. When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. *Semin Nephrol.* 2014;34(6):612-625. doi:10.1016/j.semnephrol.2014.09.004
4. Cavalier E, Souberbielle J-C, Delanaye P. PTH determination in hemodialyzed patients—a laboratory perspective. *Semin Dial.* 2019;32(6):490-492. doi:10.1111/sdi.12844
5. Evenepoel P, Bover J, Ureña Torres P. Parathyroid hormone metabolism and signaling in health and chronic kidney disease. *Kidney Int.* 2016;90(6):1184-1190. doi:10.1016/j.kint.2016.06.041
6. Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. *Am J Kidney Dis.* 2016;67(4): 559-566. doi:10.1053/j.ajkd.2015.06.023
7. Couttenye MM, D'Haese PC, Van Hoof VO, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. *Nephrol Dial Transplant.* 1996;11(6):1065-1072.
8. De Oliveira RA, Barreto FC, Mendes M, et al. Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. *Kidney Int.* 2015;87(5):1039-1045. doi:10.1038/ki.2014.372

9. Nizet A, Cavalier E, Stenvinkel P, Haarhaus M, Magnusson P. Bone alkaline phosphatase: an important biomarker in chronic kidney disease–mineral and bone disorder. *Clin Chim Acta*. 2020;501:198-206. doi:10.1016/j.cca.2019.11.012
10. Koivula M-K, Risteli L, Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. *Clin Biochem*. 2012;45(12):920-927. doi:10.1016/j.clinbiochem.2012. 03.023
11. Melkko J, Hellevik T, Risteli L, Risteli J, Smedsrød B. Clearance of NH₂-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. *J Exp Med*. 1994;179(2):405-412. doi:10.1084/ jem.179.2.405
12. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. *J Bone Miner Res*. 2000;15(7):1337-1345. doi:10.1359/jbmr.2000.15.7.1337
13. Evenepoel P, Cavalier E, D’Haese PC. Bone biomarkers in de novo renal transplant recipients. *Clin Chim Acta*. 2020;501(2019):179-185. doi:10.1016/j.cca.2019.10.035
14. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604-612. doi:10.7326/0003-4819-150-9200905050-00006
15. Bouillon R, Van Herck E, Jans I, Tan BK, Van Baelen H, De Moor P. Two direct (nonchromatographic) assays for 25hydroxyvitamin D. *Clin Chem*. 1984;30(11):1731-1736. doi: 10.1093/clinchem/30.11.1731
16. Bouillon R, Coopmans W, Degroote DE, Radoux D, Eliard PH. Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. *Clin Chem*. 1990;36(2):271-276. doi:10.1093/clinchem/36.2.271
17. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Committee. *J Bone Miner Res*. 2013;28(1):2-17. doi:10.1002/ jbmr.1805
18. Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. *J Am Soc Nephrol*. 2000;11(6):1093-1099. doi:10.1681/ASN. V1161093
19. Behets GJ, Spasovski G, Sterling LR, et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. *Kidney Int*. 2015;87(4):846-856. doi:10.1038/ki.2014.349
20. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology*. 1982;143(1):29-36. doi:10.1148/radiology.143.1.7063747
21. Liu X. Classification accuracy and cut point selection. *Stat Med*. 2012;31(23):2676-2686. doi:10.1002/sim.4509
22. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Methods in health service research: an introduction to Bayesian methods in health technology assessment. *BMJ*. 1999;319(7208):508512. doi:10.1136/bmj.319.7208.508
23. Salam S, Gallagher O, Gossiel F, Paggiosi M, Khwaja A, Eastell R. Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy. *J Am Soc Nephrol*. 2018;29(5):1557-1565. doi:10.1681/ASN.2017050584
24. Lima F, Mawad H, El-Husseini AA, Davenport DL, Malluche HH. Serum bone markers in ROD patients across the spectrum of decreases in GFR: activin A increases before all other markers. *Clin Nephrol*. 2019;91(4):222-230. doi:10.5414/CN109650

25. Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. *J Am Soc Nephrol.* 1996;7(3):506-512. doi:10.1681/ASN.V73506
26. Fletcher S, Jones RG, Rayner HC, et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. *Nephron.* 1997;75(4):412-419. doi:10.1159/000189578
27. Bervoets ARJ, Spasovski GB, Behets GJ, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. *Am J Kidney Dis.* 2003;41(5):997-1007. doi:10.1016/S0272-6386(03)00197-5
28. Lehmann G, Ott U, Kaemmerer D, Schuetze J, Wolf G. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease at ages 3-5. *Clin Nephrol.* 2008;70(4):296-305.
29. Cavalier E, Lukas P, Carlisi A, Gadisseur R, Delanaye P. Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters. *Clin Chim Acta.* 2013;425:117-118. doi:10.1016/j.cca.2013.07.016
30. Jørgensen HS, David K, Salam S, Evenepoel P. Traditional and non-traditional risk factors for osteoporosis in CKD. *Calcif Tissue Int.* 2021;108(4):496-511. doi:10.1007/s00223-02000786-0
31. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. *J Clin Endocrinol Metab.* 1996;81(11):3923-3929. doi:10.1210/jcem.81.11.8923839
32. Einbinder Y, Benchetrit S, Golan E, Zitman-Gal T. Comparison of intact PTH and bio-intact PTH assays among non-dialysis dependent chronic kidney disease patients. *Ann Lab Med.* 2017;37(5):381-387. doi:10.3343/alm.2017.37.5.381
33. Evenepoel P, Meijers BKI, de Jong H, et al. Recovery of hyperphosphatemia and renal phosphorus wasting one year after successful renal transplantation. *Clin J Am Soc Nephrol.* 2008;3(6):1829-1836. doi:10.2215/CJN.01310308
34. Wolf M, Weir MR, Kopyt N, et al. A prospective cohort study of mineral metabolism after kidney transplantation. *Transplantation.* 2016;100(1):184-193. doi:10.1097/TP.0000000000000823
35. Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single centre study. *Nephrol Dial Transplant.* 2004;19(5):1281-1287. doi:10.1093/ndt/gfh128
36. Evenepoel P, Claes K, Meijers B, et al. Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. *Nephrol Dial Transplant.* 2020;35(4):697-705. doi:10.1093/ndt/gfy306
37. Neves CL, Dos Reis LM, Batista DG, et al. Persistence of bone and mineral disorders 2 years after successful kidney transplantation. *Transplantation.* 2013;96(3):290-296. doi:10.1097/TP.0b013e3182985468
38. Højsager FD, Rand MS, Pedersen SB, Nissen N, Jørgensen NR. Fracture-induced changes in biomarkers CTX, PINP, OC, and BAP—a systematic review. *Osteoporos Int.* 2019;30(12):2381-2389. doi:10.1007/s00198-019-05132-1

39. Szulc P. The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis. *Clin Biochem.* 2012;45(12):907-919. doi:10.1016/j.clinbiochem.2012.01.022
40. Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. *N Engl J Med.* 2018;379(26):2547-2556. doi:10.1056/NEJMcp1800214
41. Ueda M, Inaba M, Okuno S, et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. *Am J Kidney Dis.* 2002;40(4):802-809. doi:10.1053/ajkd.2002.35692
42. Shidara K, Inaba M, Okuno S, et al. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. *Calcif Tissue Int.* 2008;82(4):278-287. doi:10.1007/s00223008-9127-4
43. Chavassieux P, Portero-Muzy N, Roux JP, Garnero P, Chapurlat R. Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women? *J Clin Endocrinol Metab.* 2015;100(12):4662-4668. doi:10.1210/jc.2015-2957
44. Marques IDB, Araújo MJCLN, Gracioli FG, et al. A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation. *J Am Soc Nephrol.* 2019;30(2):355365. doi:10.1681/ASN.2018060656
45. Hiramatsu R, Ubara Y, Sawa N, Sakai A. Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study. *Nephrol Dial Transplant.* 2021;36(10):1900-1907. doi:10.1093/ndt/gfaa359
46. Evenepoel P, D'Haese P, Bacchetta J, et al. Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative-a position paper. *Nephrol Dial Transplant.* 2017;32(10):1608-1613. doi:10.1093/ndt/gfw468